Lyell Immunopharma (LYEL) Price to Sales (2021 - 2026)
Powered by 
Analysis
Lyell Immunopharma (LYEL) Price to Sales (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Lyell Immunopharma | 335.97 Mn | 335.97 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 82,181.96 |
| Mar 31, 2026 | 233,983.75 |
| Dec 31, 2025 | 87,687.09 |
| Sep 30, 2025 | 20,888.97 |
| Jun 30, 2025 | 16,388.26 |
| Mar 31, 2025 | 22,694.69 |
| Dec 31, 2024 | 17,156.42 |
| Sep 30, 2024 | 10,413.48 |
| Jun 30, 2024 | 28,548.08 |
| Mar 31, 2024 | 189,495.73 |
| Dec 31, 2023 | 37,898.35 |
| Sep 30, 2023 | 14,809.90 |
| Jun 30, 2023 | 29,565.40 |
| Mar 31, 2023 | 9,062.74 |
| Dec 31, 2022 | 17.90 |
| Sep 30, 2022 | 608,976.43 |
| Jun 30, 2022 | 45.08 |
| Mar 31, 2022 | 2,241.20 |
| Dec 31, 2021 | 372.79 |
| Sep 30, 2021 | 1,288.16 |